Dual interim report of low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer

Journal of Applied Research

Volumn 5, Issue 2, 2005, Pages 331-344

  Kitamura, Tadaichi ^a   Nishimatsu, Hiroaki ^a   Suzuki, Motofumi ^a   Mohammed, Rafiq ^a   Tomita, Kyouichi ^a   Takahashi, Satoru ^a   Takeuchi, Takumi ^a   Ohota, Nobutaka ^a   Kameyama, Shuji ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b Kanto Teishin Hospital   (Japan)

Author keywords

Advanced prostate cancer; Estramustine phosphate; Low dose EMP monotherapy; Previously untreated prostate cancer; Very low dose EMP with LH RH agonist

Indexed keywords

ACETYLSALICYLIC ACID; ESTRAMUSTINE PHOSPHATE; FAMOTIDINE; GONADORELIN AGONIST; GOSERELIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BRAIN INFARCTION; CANCER COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG WITHDRAWAL; EDEMA; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; IMPOTENCE; LIVER DYSFUNCTION; LONG TERM CARE; LOW DRUG DOSE; LUNG INFARCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PROSTATE CANCER; RASH; SIDE EFFECT; STOMACH PAIN; STOMACH ULCER; THROMBOEMBOLISM; TOXICITY; TREATMENT OUTCOME; VOMITING;

EID: 21844446323     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Smith DC. Chemotherapy for hormone refractory prostate cancer. Urologic Clinics North America. 1999;26:323-331.
2. Perry CM, McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging. 1995;7:49-74.
3. Olmstead J: Microtubule associated proteins. Ann Rev Cell Biol 1986;2:419-455.
4. Van Poppel H, Baert L. The present role of estramustine phosphate in advanced prostate cancer. In: European Organization for Research and Treatment of Cancer. Genitourinary Croup Monograph 10-Urological Oncology: Reconstructive Surgery, Organ Conservation, and Restoration of Function. Hoboken, NJ: Wiley-Liss, Inc; 1991;323-341.
5. Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol. 1997;15:13-19.
6. Pienta KJ, Fisher EI, Eisenberger MA, et al. A Phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407). Prostate. 2001;46:257-26l.
7. Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol. 2001;19:44-53.
8. Petrylak DP, Macarthur RB, O'Connor J, et al. Phase 1 trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999;17:958-967.
9. Kitamura T, Nishimatsu H, Hamamoto T, Tomita K, Takeuchi T, Ohta N. EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer. Expert Rev Anticancer Ther. 2002;2:59-71.
10. Andersson L, Berlin T, Boman J, et al. Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma. A randomized study. Scand J Urol Nephrol. 1980;55:143-145.
11. Benson RC Jr, Gill GM. Estramustine phosphate compared with diethylstilbestrol: a randomized, double-blind, crossover trial for stage D prostate cancer. Am J Clin Oncol. 1986;9:341-351.
12. Hauchecorne J. French multicentre study on the use of estramustine phosphate versus diethylstilbestrol. In: Prostate Cancer, Part B: Imaging Techniques, Radiotherapy, Chemotherapy and Management Issues. New York, NY; Alan R. Liss Inc; 1987:229-234.
13. Kuss R, Khoury S, Richard F, Fourcade F, Frantz P, Capelle JP. Estramustine phosphate in the treatment of advanced prostatic cancer. Brit J Urol. 1980;52:29-33.
14. Smith PH, De Pauw M, Robinson M, et al. EORTC Urological Group: Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762. Urology. 1984;6(suppl):64-68.
15. The Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 1984;311:1281-1286.
16. Tyrrell CJ, Altwein JE, Klippel F, et al. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue Goserelin Acetate alone and with Flutamide in the treatment of advanced prostate cancer. J Urol. 1991;146:1321-1326.
17. Gunnarsson PO, Davidsson T, Andersson S-B, Backman C, Johansson S-A. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol. 1990;38:189-193.
18. Kitamura T. Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer. Int J Urol. 2001;8:33-36.
19. Marubini E, Valsecchi MG. Analyzing survival data from clinical trials and observational studies. Chichester, UK: John Wiley & Sons Ltd; 1995.
20. Takayasu H, Shida K, Momose S, et al. Clinical study on the treatment of prostatic carcinoma with Estracyt. Nishinihon J Urol. 1980;42:715-731.
21. Takenaka I, Soramoto S, Kagawa S, et al. Multicenter randomized clinical trial comparing estracyt mono-therapy with combined androgen blockade therapy (CAB) in the treatment of advanced prostate cancer. Nishinihon J Urol. 2001;63:1-9.
22. Saito S, Nakajima J, Nakajima Y, et al. Clinical efficacy of Leuprolide Acetate and combined treatment with Estramustine for advanced prostate cancer. Jpn J Urol. 2001;92:682-693.
23. Iversen P, Christensen MG, Friis E, et al. A phase III trial of Zoladex and Flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer. 1990;66(5 suppl):1058-1066.
24. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without Flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036-1042.
25. Fourcade RO, Cariou G, Coloby P, et al. Total androgen blockade with Zoladex plus Flutamide vs. Zoladex alone in advanced prostatic carcinoma: Interim report of a multicenter, double-blind, placebo-controlled study. Eur Urol. 1990;18(suppl 3):45-47.
26. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002;95:361-376.
27. Noguchi M, Noda S, Yoshida M, et al. Estramustine may offer benefits over Flutamide in chemohormonal therapy for metastatic prostate cancer. Int J Urol. 2004;11:103-109.